Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H18O5 |
Molecular Weight | 350.3646 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1OC2=CC3=C(C=CO3)C(OCCCCOC4=CC=CC=C4)=C2C=C1
InChI
InChIKey=KINMYBBFQRSVLL-UHFFFAOYSA-N
InChI=1S/C21H18O5/c22-20-9-8-16-19(26-20)14-18-17(10-13-24-18)21(16)25-12-5-4-11-23-15-6-2-1-3-7-15/h1-3,6-10,13-14H,4-5,11-12H2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/25175978Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19282171 | https://www.ncbi.nlm.nih.gov/pubmed/25734225 | https://www.ncbi.nlm.nih.gov/pubmed/23636064 | https://www.ncbi.nlm.nih.gov/pubmed/16099841
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25175978
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19282171 | https://www.ncbi.nlm.nih.gov/pubmed/25734225 | https://www.ncbi.nlm.nih.gov/pubmed/23636064 | https://www.ncbi.nlm.nih.gov/pubmed/16099841
PAP-1 (5-(4-phenoxybutoxy)psoralen) is the selective inhibitor of Kv1.3, voltage-gated K+ channel, that is highly expressed in cell membranes of activated effector memory T cells (TEM). The blockade of Kv1.3 results in membrane depolarization and inhibition of TEM proliferation and function. PAP-1 is 23-fold selective over Kv1.5, 33- to 125-fold selective over other Kv1-family channels, and 500- to 7500-fold selective over Kv2.1, Kv3.1, Kv3.2, Kv4.2, HERG, calcium-activated K+ channels, Na+, Ca2+, and Cl- channels. PAP-1 does not exhibit cytotoxic or phototoxic effects, is negative in the Ames test, and affects cytochrome P450-dependent enzymes only at micromolar concentrations. PAP-1 potently inhibits the proliferation of human TEM cells and suppresses delayed-type hypersensitivity, a CD4+ T cell-mediated reaction, in rats when administered intraperitoneally or orally. PAP-1 further effectively treats allergic contact dermatitis, a CD8+ T cell-mediated reaction.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4633 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19282171 |
10.0 nM [IC50] | ||
Target ID: CHEMBL4306 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20974533 |
3450.0 nM [IC50] | ||
Target ID: CHEMBL2086 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25734225 |
250.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. | 2005 Nov |
|
Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. | 2007 Nov |
|
4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3. | 2009 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23636064
PAP-1 (6mg/kg,0.2ml injection volume per graft) injections were given to mice daily for 31 days, intradermally into each graft, following injection of the NKG2D/CD56-enriched cells.
PAP-1
Route of Administration:
Transdermal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16099841
Jurkat E61 and MEL cells were seeded at 5 x 10^5 cells/ml in 12-well plates. Compounds (PAP-1) were added at concentrations of 10 nM, 100 nM, and 10 _M in a final DMSO concentration of 0.1%, which was found not to affect cell viability. After 48 h, the cells in each well were well mixed and resuspended, and the number of trypan blue-positive cells in three aliquots from each well was determined under a light microscope. The test was repeated twice.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000042330
Created by
admin on Sat Dec 16 09:51:25 GMT 2023 , Edited by admin on Sat Dec 16 09:51:25 GMT 2023
|
PRIMARY | |||
|
A62C114Q0Q
Created by
admin on Sat Dec 16 09:51:25 GMT 2023 , Edited by admin on Sat Dec 16 09:51:25 GMT 2023
|
PRIMARY | |||
|
870653-45-5
Created by
admin on Sat Dec 16 09:51:25 GMT 2023 , Edited by admin on Sat Dec 16 09:51:25 GMT 2023
|
PRIMARY | |||
|
DTXSID80461776
Created by
admin on Sat Dec 16 09:51:25 GMT 2023 , Edited by admin on Sat Dec 16 09:51:25 GMT 2023
|
PRIMARY | |||
|
11302540
Created by
admin on Sat Dec 16 09:51:25 GMT 2023 , Edited by admin on Sat Dec 16 09:51:25 GMT 2023
|
PRIMARY |
ACTIVE MOIETY